HEALTHCARE
can .” Partnerships have to be mutually beneficial and involve providing better services to the communities they are in , he adds , or they will find other avenues to do business .
PAML ’ s strategic partnerships include one with the molecular technology company , Axela , a spin-out of the University of Toronto . “ They have a very unique technology that we see as beneficial for our partners , so we partner with them and help develop assays that can be used in the American market ,” says Dr Velázquez . Partnerships account for many advances , though PAML also prides itself on its ability to produce innovative resources in-house .
One of these resources is a new , progressive cost-accounting system . “ We ’ re going to see more bundle payments , more population health management , more regionally integrated networks and more valuebased care ,” says Dr Velázquez . “ So , the common denominator to all those is not revenue . The common denominator is that you must understand your cost structure ,
www . paml . com 99
Francisco Velázquez
President & CEO
Francisco R . Velázquez , M . D ., S . M . is the President and Chief Executive Officer for PAML , LLC and PAML Ventures . Prior to joining PAML , Dr . Velázquez was Managing Director for the Quest Diagnostics Nichols Institute , and Vice President for Focus Diagnostics , in San Juan Capistrano and Cypress , California respectively . Dr . Velázquez trained at the Mallory Institute of Pathology in Boston , the Boston University Medical Center and is Board Certified by the American Board of Pathology . Subsequent to his training , Dr . Velázquez obtained a Masters in Health Care Management and Policy at Harvard University School of Public Health , Boston , Massachusetts .